INCY

SEC source: 0001209191-23-005452 · doc4.xml · nonDerivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,835

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 40,178 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001209191-23-005452 · doc4.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-004563 · doc4.xml · derivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,194

Underlying: Common Stock · 14,194 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004563 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,673

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 40,178 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004561 · doc4.xml · nonDerivative · entry 1

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,338

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Jonathan Dickinson's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 19,311 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. The aggregate amount also includes the additional restricted stock granted on January 20, 2023.

SEC source: 0001209191-23-004569 · doc4.xml · derivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,194

Underlying: Common Stock · 14,194 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004569 · doc4.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,835

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 40,178 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004568 · doc4.xml · derivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,096

Underlying: Common Stock · 27,096 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004568 · doc4.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,001

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 92,490 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004567 · doc4.xml · derivative · entry 2

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,968

Underlying: Common Stock · 2,968 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 after one year and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004567 · doc4.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,439

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the award, subject to Thomas Tray's continued service with the issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 15,080 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. The aggregate amount also includes the additional restricted stock granted on January 20, 2023.

SEC source: 0001209191-23-004566 · doc4.xml · derivative · entry 2

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,515

Underlying: Common Stock · 24,515 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004566 · doc4.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,639

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 65,995 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004565 · doc4.xml · derivative · entry 2

Pasquale Maria E · CIK 0001736295 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,354

Underlying: Common Stock · 19,354 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004565 · doc4.xml · nonDerivative · entry 1

Pasquale Maria E · CIK 0001736295 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,524

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 49,571 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004564 · doc4.xml · derivative · entry 3

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,449

Underlying: Common Stock · 86,449 shares

Expires 2033-01-19

F4 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004564 · doc4.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,139

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 276,741 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004560 · doc4.xml · derivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,354

Underlying: Common Stock · 19,354 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 the remainder vesting monthly over three years.

SEC source: 0001209191-23-004560 · doc4.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,654

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 66,790 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004562 · doc4.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,373

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Morrissey's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes an aggregate of 30,833 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. The aggregate amount also includes the additional restricted stock granted on January 20, 2023.

SEC source: 0001209191-23-004558 · doc4.xml · derivative · entry 2

Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,128

Underlying: Common Stock · 16,128 shares

Expires 2033-01-19

F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years.

SEC source: 0001209191-23-004558 · doc4.xml · nonDerivative · entry 1

Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,682

F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded.

F2 · balance_after: This includes an aggregate of 41,531 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023.

SEC source: 0001209191-23-004404 · doc4.xml · nonDerivative · entry 1

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,179

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 13,152 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-004403 · doc4.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,214

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 24,674 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-003696 · doc4.xml · nonDerivative · entry 2

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,284

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 18,671 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-003695 · doc4.xml · nonDerivative · entry 2

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,319

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 30,193 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-003696 · doc4.xml · nonDerivative · entry 1

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,371

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 18,671 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-003695 · doc4.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,406

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 30,193 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-002319 · doc4.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,493

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 33,068 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-002318 · doc4.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,021

F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: This includes an aggregate of 87,510 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0001209191-23-002310 · doc4.xml · nonDerivative · entry 1

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,458

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 21,546 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-000812 · doc4.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 33,422,926

F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: Includes beneficial ownership of 8,563 shares of Common Stock previously issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees, 6,869 shares of Common Stock received previously from vested restricted stock units (each, an "RSU") and 195,000 shares of Common Stock received previously from the exercise of 195,000 non-qualified stock options to purchase Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion.

F8 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, Stock Options, Common Stock issued upon exercise of Stock Options, RSU's payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest).

F9 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F10 · ownership.nature: The disclosure of the grant of RSUs reported on this form is a single grant of 397 RSUs on Table I. The 397 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F11 · ownership.nature: 397 shares of Common Stock issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of the Funds.

F12 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001209191-23-000812 · doc4.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,945,018

F4 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: Includes beneficial ownership of 8,563 shares of Common Stock previously issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees, 6,869 shares of Common Stock received previously from vested restricted stock units (each, an "RSU") and 195,000 shares of Common Stock received previously from the exercise of 195,000 non-qualified stock options to purchase Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion.

F8 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, Stock Options, Common Stock issued upon exercise of Stock Options, RSU's payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest).

F9 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F10 · ownership.nature: The disclosure of the grant of RSUs reported on this form is a single grant of 397 RSUs on Table I. The 397 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F11 · ownership.nature: 397 shares of Common Stock issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of the Funds.

SEC source: 0001209191-23-000806 · doc4.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,388

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-000801 · doc4.xml · nonDerivative · entry 1

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,473

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-23-000800 · doc4.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,669

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-22-062808 · doc4.xml · derivative · entry 8

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2028-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years.

SEC source: 0001209191-22-062808 · doc4.xml · derivative · entry 7

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,866 shares

Expires 2023-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning May 9, 2016, options become exercisable in 25 installments, with the first 33.33% vesting on May 9, 2017 and the remainder vesting monthly over two years.

SEC source: 0001209191-22-062808 · doc4.xml · nonDerivative · entry 6

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,855

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 35,198 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001209191-22-062808 · doc4.xml · nonDerivative · entry 5

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,509

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

SEC source: 0001209191-22-062808 · doc4.xml · nonDerivative · entry 4

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,313

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

SEC source: 0001209191-22-062808 · doc4.xml · nonDerivative · entry 3

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-062808 · doc4.xml · nonDerivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,313

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

SEC source: 0001209191-22-062808 · doc4.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-062319 · doc4.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,606

F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 12,247 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-22-060896 · doc4.xml · nonDerivative · entry 1

Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,702

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 36,551 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0001209191-22-054184 · doc4.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,367

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly Board committee retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0001209191-22-052801 · doc4.xml · derivative · entry 2

Schaffert Susanne · CIK 0001938363 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,751

Underlying: Common Stock · 6,751 shares

Expires 2032-10-02

F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan).

SEC source: 0001209191-22-052801 · doc4.xml · nonDerivative · entry 1

Schaffert Susanne · CIK 0001938363 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,625

F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0001209191-22-052206 · doc4.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 33,422,529

F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, (the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: Includes beneficial ownership of 8,106 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 6,869 shares of Common Stock received previously from vested restricted stock units (each, an "RSU") and 195,000 shares of Common Stock received previously from the exercise of 195,000 non-qualified stock options to purchase Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion.

F8 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, Stock Options, Common Stock issued upon exercise of Stock Options, RSU's payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest).

F9 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F10 · ownership.nature: The disclosure of the grant of RSUs reported on this form is a single grant of 457 RSUs on Table I. The 457 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F11 · ownership.nature: 457 shares of Common Stock issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of the Funds.

F12 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.